Encapsulated drug compositions and methods of use thereof

Abstract

Various aspects of the present disclosure provide compositions, coatings and implantable devices including a drug and an excipient. In certain embodiments the excipient and the drug are present at a weight ratio of between 10 to 1 and 1 to 10 drug to excipient. In certain other embodiments, the excipient and the drug form particles in which the drug is encapsulated by the excipient. Other aspects of the disclosure provide methods of manufacturing and using such compositions, coatings and implantable devices.

1 . A medical device comprising:
 a base structure having a surface, and   a coating on the surface comprising a drug and an excipient, wherein the drug and excipient are present at a weight ratio of between 10 to 1 and 1 to 10 drug to excipient, and wherein the excipient is selected from the group consisting of a gallate containing compound, epi gallo catechin gallate, tannic acid and epi catechin gallate.   
     
     
         2 . The medical device of  claim 1 , wherein the drug is a restenosis-inhibiting agent. 
     
     
         3 . The medical device of  claim 1 , wherein the excipient is selected from a group consisting of epi gallo catechin gallate and tannic acid and epi catechin gallate. 
     
     
         4 . The medical device of  claim 3 , wherein the excipient is tannic acid. 
     
     
         5 . The medical device of  claim 3 , wherein the excipient is epi gallo catechin gallate. 
     
     
         6 . The medical device of  claim 1 , wherein the coating consists essentially of the excipient and the drug. 
     
     
         7 . The medical device of  claim 1 , wherein the drug is selected from the group consisting of an immunosuppressive agent, an antiproliferative agent, a microtubule stabilizing agent, a restenosis-inhibiting agent, a smooth muscle cell inhibitor and an inhibitor of the mammalian target of rapamycin. 
     
     
         8 . The medical device of  claim 1 , wherein the drug is selected from the group consisting of sirolimus, pimecrolimus, tacrolimus, everolimus, zotarolimus, novolimus, myolimus, temsirolimus, deforolimus and biolimus. 
     
     
         9 . The medical device of  claim 1 , wherein the drug is paclitaxel. 
     
     
         10 . The medical device of  claim 9 , wherein the paclitaxel is selected from the group consisting of amorphous paclitaxel, dihydrate paclitaxel, anhydrous crystalline paclitaxel and a mixture of at least two thereof. 
     
     
         11 . The medical device of  claim 9 , wherein the paclitaxel is present in an amorphous and a crystalline form. 
     
     
         12 . The medical device of  claim 1 , wherein the coating is free of a polymer or non-polymer carrier matrix. 
     
     
         13 . The medical device of  claim 1 , wherein the coating comprises less than 1 percentage by weight of a polymer or non-polymer carrier matrix 
     
     
         14 . (canceled) 
     
     
         15 . The medical device of  claim 1 , wherein the medical device is a stent. 
     
     
         16 . The medical device of  claim 1 , wherein the medical device is selected from the group consisting of a stent, a vascular stent, a uretheral stent, a catheter, a stent graft, a wire guide, and a cannula. 
     
     
         17 . The medical device of  claim 1 , wherein the drug is present in more than one polymorphic form. 
     
     
         18 . The medical device of  claim 1 , wherein the excipient is present in an amount effective to increase a rate of release of the drug from the medical device when implanted in a patient. 
     
     
         19 . The medical device of  claim 1 , wherein the drug is a water-insoluble drug. 
     
     
         20 . (canceled) 
     
     
         21 . A composition comprising:
 a drug;   an excipient selected from the group consisting of epi gallo catechin gallate and tannic acid; and   a pharmaceutically acceptable carrier suitable for topical administration.   
     
     
         22 . The composition of  claim 21 , wherein the drug is a water-insoluble drug.